Introduction {#sec1-1}
============

Cutaneous leishmaniasis (CL) refers to chronic skin lesions with different clinical forms, courses of disease, and tissue reactions. In the Old World, the disease is caused by *Leishmania aethiopica*, *Leishmania major*, *Leishmania tropica*, and *Leishmania infantum*, and is transmitted to humans by *Phlebotomus* sand flies. Over 12 million people have been estimated to be infected with the *Leishmania* parasites.\[[@ref1]\] On the other hand, Iran, particularly Isfahan province, has been identified as an endemic area of CL caused by *L. major*.\[[@ref2]\]

Despite the self-limiting nature of CL, treatment is generally preferred due to various reasons. CL treatment without delay can prevent not only scarring but also necrosis and rapid development of lesions following secondary bacterial infections. On the other hand, 10% of untreated lesions will remain unhealed and become chronic. Therefore, effective treatment of CL through chemotherapy is strongly recommended.\[[@ref3]\]

During the past 60 years, pentavalent antimonial (SbV) compounds, such as meglumine antimoniate (Glucantime) and sodium stiboglucunate (Pentostam), have been the first-line treatment for all forms of leishmaniasis.\[[@ref4]\] Being basically regarded as a treatment for schistosomiasis, antimonial salts were first used to treat human leishmaniasis in 1946.\[[@ref5]\] Until 1970, the treatment involved the administration of low doses of SbV (10 mg/kg; maximum: 600 mg) for 6--10 days. However, since this method failed in 30% of the cases,\[[@ref6]\] in 1984, the World Health Organization proposed the dosage to be increased to 20 mg/kg/day (maximum: 850 mg) for 20 days.\[[@ref7]\] Resistance of *Leishmania* species to antimonial drugs has alarmingly increased during the past decades.\[[@ref8][@ref9]\]

SbV compounds are administered through intramuscular (IM) and intralesional (IL) injections. The compounds reach their peak values within 2 h from the IM injection and 50% of the drug is excreted through the kidneys during the first 24 h.\[[@ref10]\]

Variation in therapeutic responses to SbV compounds in the past 50 years,\[[@ref6]\] numerous cases of treatment failure around the world and in Iran,\[[@ref11][@ref12]\] and resistance to SbV therapy\[[@ref13]\] have complicated the administration of the first-line drugs for leishmaniasis.\[[@ref14]\]

Reduction of efficacy of SbV was reported by Lira *et al*., Hadighi *et al*., Rojas *et al*., and Yardely *et al*.\[[@ref8][@ref15][@ref16][@ref17]\] in several endemic areas. Wide differences in the sensitivity of various CL isolates to SbV compounds were discovered via amastigote--macrophage model.\[[@ref18]\] In Guatemala, Pentostam was reported to treat successfully 96% of CL caused by *Leishmania braziliensis*. Nevertheless, the rate was as low as 57% when the disease was caused by *L. mexicana*.\[[@ref19]\]

Iran is an endemic area for CL where the disease is considered as a regional health issue.\[[@ref20][@ref21]\] Since Glucantime is the first-line treatment for leishmaniasis, a proper understanding of its mechanism of action is essential. Meanwhile, besides having to deal with proven resistance of *L. tropica* to Glucantime, Iranian health authorities have been recently faced with high prevalence of unresponsiveness of zoonotic CL (ZCL) cases to the drug.\[[@ref22]\] Hence, the present study collected *L. major* isolates from patients with resistance phenotype and investigated the presence/absence of resistance to Glucantime both *in vitro* and *in vivo*. We believe that our findings will be beneficial in future decisions to resolve patients' problems with no response to treatment.

Materials and Methods {#sec1-2}
=====================

In this experimental study, 10 non-healing CL patients despite receiving at least one full course of treatment with Glucantime were selected. Used *L. major* strain (MRHO/IR/75/ER) was the drug-sensitive strain, that isolated from naturally infected *Rhombomys opimus*, and has no human origin, therefore had not been exposed to any anti-leishmaniasis drugs.

Direct microscopy was used as a tool for detecting parasites of the smeared slides from the lesions of cases. Small amounts of the samples were then added to vials containing 0.5 ml brain-heart infusion (BHI) medium and transferred to the parasitology laboratory of Isfahan University of Medical Sciences (Isfahan, Iran) to isolate the parasite.

Culture of the parasites {#sec2-1}
------------------------

The isolated samples were cultured in modified Novy-MacNeal-Nicolle (NNN) medium with 100 µg/ml streptomycin and 100 IU/ml penicillin G at 24 ± 1°C. They were transferred to RPMI 1640 medium supplemented with 20% inactivated fetal calf serum (FCS) with 100 µg/ml streptomycin and 100 IU/ml penicillin G at 24 ± 1°C. *L. major* (MRHO/IR/75/ER) and *L. tropica* (MRHO/IR/02/Mash10) strains were also cultured by a similar process and considered as standard strains.

Species identification {#sec2-2}
----------------------

Nested polymerase chain reaction (PCR) was performed to identify the isolated species. DNA of the cultured promastigotes was extracted using a commercial kit (GeNet Bio, Seoul, Korea) and according to the manufacturer\'s instructions. DNA extraction was confirmed through spectrophotometry. Finally, the first and second stages of nested PCR were conducted to detect the kinetoplastic DNA (kDNA) by using CSB7XR and CSB2XF as first primers and 13Z and LiR as second primers\[[@ref23]\] \[[Table 1](#T1){ref-type="table"}\].

###### 

Primers used in nested PCR
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*L. major* (MRHO/IR/75/ER) and *L. tropica* (MHOM/IR/02/Mash10) were used as standards in nested PCR.

*In vitro* experiments {#sec2-3}
----------------------

J744 cell line (purchased from Pasteur Institute of Iran, Tehran, Iran) was incubated in cell culture flasks containing RPMI 1640 medium supplemented with decomplemented FCS at 37°C and in the presence of 5% CO~2~. After cell growth, a scraper was utilized to detach cells from the plates. Subsequent to Neubauer chamber cell counting, 2 × 10^6^ cells/well were transferred to a six-well plate with a 22 × 22 mm^2^ coverslip on the bottom. RPMI 1640 medium (2 ml) supplemented with inactivated FCS 20%, penicillin, and streptomycin was added to the cells and the plates were incubated at 37°C for 5--6 days. In order to count intracellular amastigotes before and after exposure to the drug (control and case, respectively), two wells were dedicated to each sample.

Stationary phase promastigotes from each patient and the standard *L. major* strain (MRHO/IR/75/ER) were separately added to the grown, adhesive J774 macrophages at a 7:1 ratio. After 4 h of incubation at 34°C, the extracellular parasites were washed with phosphate buffered saline (PBS) and the medium was replaced with fresh RPMI 1640 supplemented with inactivated FCS 15%. The plates were incubated at 37°C in the presence of 5% CO~2~ for an additional 24 h.

In the next stage, each culture plate was exposed to 7.2 µM pure Glucantime powder equal to ED50 of the drug.\[[@ref23]\] For this purpose, the supernatant was discarded, 2 ml of fresh culture medium containing Glucantime was added, and the plates were incubated for 72 h. Then, the coverslips were removed, fixed with methanol, and stained with Giemsa.

In microscopic examination, the number of intracellular amastigotes in coverslips containing cells and parasites with and without the drug (case and control, respectively) was calculated. This process involved the assessment of 100 macrophages/plate, counting the existing amastigotes, and calculating the average of obtained values. The final numbers of amastigotes in the isolates of patients before and after exposure to the drug were compared with the values obtained from standard strains.

*In vivo* experiments {#sec2-4}
---------------------

Female BALB/c mice (4--6 weeks old) were purchased from Pasteur Institute of Iran (Tehran, Iran) and were divided into 11 groups, with 10 mice in each group and housed in the animal facility of School of Medicine, Isfahan University of Medical Sciences (Isfahan, Iran). A total of 2 × 10^6^ promastigote isolates of patients and standard *L. major*, which had been cultured and had reached the stationary phase, were intradermally injected to the base of the mice\'s tail.

The mice were treated with daily IL injections of 60 mg/kg home-prepared solution of Glucantime for 2 weeks.\[[@ref24]\] In order to determine the size of the lesions, two perpendicular diameters of the lesions were measured using a caliper and the averages of obtained values were calculated. The measurements were repeated at baseline, on days 7 and 14, and 4 weeks after the cessation of treatment.

The parasite burden of the lesions before and after treatment was evaluated by smearing lesion secretions on slides, Giemsa staining, and parasite counting based on the following method.

The mean numbers of amastigotes in 10 microscopic fields with oil-immersion lens were computed and scored as + 1 to + 4 if the number of amastigotes was 1, 2--10, 11--100, and 101--1000, respectively. If no parasite was observed on the slide, the sample was considered as negative.

Ultimately, the therapeutic effect of Glucantime was assessed by comparing the sizes and parasite burden of the lesions caused by isolates from the patients and the standard strains. Paired and independent *t*-tests were applied to analyze the data. All analyses were performed in SPSS version 20 and at *P* value \< 0.05.

Results {#sec1-3}
=======

Species identification of the isolates {#sec2-5}
--------------------------------------

The product of the second stage of nested PCR of all isolates of patients with resistance phenotype on agarose gel 1% showed amplified band of 560 bp. Comparison of the results with reference bands of *L. major* (MRHO/IR/75/ER) and *L. tropica* (MHOM/IR/02/Mash 10) suggested all samples to be *L. major*. In fact, *L. tropica* shows the 750 bp band \[[Figure 1](#F1){ref-type="fig"}\].

![Agarose gel electrophoresis of second phase of nested PCR product of amastigotes genomic DNA isolated from patients with resistance phenotype. Lane M is a 50 bp DNA ladder (fermentase), C1: DNA from *L. tropica* (MHOM/IR/02/Mash10), C2: DNA from *L. major* (MRHO/IR/75/ER), lanes 1--7 are samples from non-healing individuals](ABR-6-17-g002){#F1}

Results of *in vitro* experiments {#sec2-6}
---------------------------------

After the termination of the test phase, the coverslips were removed from the case and control plates, stained with Giemsa, and the mean number of the intracellular amastigotes was calculated in 100 macrophages \[[Figure 2](#F2){ref-type="fig"}\].

![Macrophages containing phagocytosed parasites that transformed to amastigotes from promastigotes. Magnification 100×](ABR-6-17-g003){#F2}

Comparison of the number of parasites in these two stages revealed that this amount of drug had almost halved the number of parasites. Similar reductions were detected in plates containing isolates of the patients and standard *L. major* (MRHO/IR/75/ER) \[[Figure 3](#F3){ref-type="fig"}\].

![The mean number of amastigotes in 100 macrophages of the standard strain (11^th^ sample) and isolates of patients (1--10 samples) after exposure to drug](ABR-6-17-g004){#F3}

Results of *in vivo* experiments {#sec2-7}
--------------------------------

### Results of parasite burden assessments {#sec3-1}

A same decline in parasite burden was detected among all treated groups. In fact, at the end of the treatment course, the parasite was eliminated in 90% of mice with lesions caused by both isolates of patients and standard *L. major* \[[Table 2](#T2){ref-type="table"}\].

###### 

Percent of parasite burden in the groups of BALB/c mice that received isolates from individuals (group 1) and standard *L. major* (MRHO/IR/75/ER) (group 2), before and after treatment
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At the end of the treatment in groups 1 and 2, independent *t*-test showed significant differences between the case and control groups. Paired *t*-test showed no significant difference between the test and standard in groups 1 and 2 (*P* \< 0.5).

### Results of lesion size measurements {#sec3-2}

Lesion size measurements at baseline and on days 7 and 14 after the cessation of treatment were done. A significant reduction in lesion size was observed after treatment in both groups \[[Table 3](#T3){ref-type="table"}\] and there was no difference in treatment responses between the two groups. At the end of the course of treatment, the lesion size of both groups was diminished and the same response was observed on comparing the two groups.

###### 

The mean of lesions diameters (mm) after treatment in group 1 of BALB/c mice that received isolates from individuals and group 2 that received *L. major* (MRHO/IR/75/ER)
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Discussion {#sec1-4}
==========

Despite extensive research throughout the world, leishmaniasis, a disease with complex dimensions, keeps affecting people\'s lives and causes dramatic mortality and disability. SbV compounds \[e.g., meglumine antimoniate (Glucantime)\] are the main components of chemotherapy against leishmaniasis. Notwithstanding its toxicity, Glucantime is the treatment of choice for leishmaniasis in many parts of the world, including Iran.\[[@ref25]\] However, the drug has been found ineffective in increasing numbers of cases, even in the presence of healthy immune systems.\[[@ref16]\]

Unresponsiveness to treatment has been reported in patients with CL caused by *L. major* in Iran. In 2002, an epidemic of anthroponotic CL (ACL) occurred in Mashhad (a northeastern city of Iran). In a cross-sectional study in the region, Hadighi *et al*. indicated 94.2% of the isolates were *L. tropica* and 12% of them did not respond to SbV therapy. They further evaluated and followed patients in Mashhad and concluded that chemotherapy with Glucantime was unsuccessful in CL cases caused by both *L. tropica* and *L. major*.\[[@ref8]\]

Resistance to glucantime has been proven in several *Leishmania* species. For instance, in 1999, Lira and Sundar detected intrinsic resistance of *L. donovani* to this drug.\[[@ref15]\] Moreover, in other species such as *L. infantum*, relationships have been identified between clinical characteristics of the disease and the parasite\'s sensitivity to treatment.\[[@ref15][@ref26]\]

Gradual mutations of the parasite might have been responsible for the decreased sensitivity of the phenotype to treatment. Evaluations with restriction fragment length polymorphism (RFLP) and conformational sensitive gel electrophoresis (CSGE) have actually clarified mutations in drug resistance genes of *L. tropica* samples from endemic areas of Iran.\[[@ref27]\]

Since Isfahan is an endemic area of *L. major* and previous studies have mainly focused on other *Leishmania* species, the present research only studied *L. major* samples. Species identification was performed through nested PCR, which possesses high sensitivity and specificity in DNA sequencing.

Recent studies have adopted the amastigote--macrophage model to describe drug resistance mechanisms in vitro. The results of these studies have been consistent with clinical findings. In addition, the amastigote--macrophage model has been proposed as the gold standard to evaluate anti-leishmaniasis effects of different drugs.\[[@ref8][@ref15][@ref17]\] This model was used with samples isolated from patients with and without response to treatment by researchers in Bihar (India). They found the first group of patients to be three times more sensitive to the medicine compared to the second group, while there was not such a difference between promastigote stage of the isolates.\[[@ref15]\] In a study in Sudan, the clinical response of field isolates to Pentostam was similar to the results of the amastigote--macrophage model but differed from the results of the promastigote model.\[[@ref28]\] It can thus be concluded that our *in vitro* findings using the amastigote--macrophage model are highly reliable.

In the present study, isolates from patients with no response to treatment had no significant difference with the standard *L. major* strain (as the sensitive strain) in terms of sensitivity to Glucantime. Therefore, in patients with resistance phenotype to Glucantime, the parasites did not actually have intrinsic resistance and probably environmental and host factors prevented the successful treatment of the disease.

*In vivo* assessments were done to make sure that factors affecting the phenotype, which are caused by host--parasite interactions during parasite growth, have been included. We inoculated BALB/c mice with parasites isolated from selected patients. According to our findings, the treatment could successfully reduce both lesion size and parasite load in BALB/c mice model. Identical results were observed in lesions produced by the standard strain. Consequently, the absence of intrinsic resistance to Glucantime among the parasites isolated from patients with no response to treatment (resistance phenotype) can be reemphasized.

The multifactorial nature of therapeutic responses has complicated the relation between drug resistance and clinical responses. Differences in immune systems of hosts, pharmacological factors, different drug formulations and manufacturers, pharmacokinetics of the drug and its effects on drug distribution in the body, drug metabolism and excretion in different hosts should necessarily be taken into account. We used pure Glucantime powder without pharmaceutical additives. In other words, exposure of the parasites to pure drug and minimizing the effects of drug formulation can justify the greater efficacy of treatment in the current study compared to treatment modalities in health centers.

Moreover, unequal sensitivity of different *Leishmania* species to the medicine, alone or in combination with other factors, can influence treatment outcome.\[[@ref30][@ref31]\] In a study on ZCL in Saudi Arabia, the amastigote--macrophage model did not reveal any difference in the sensitivity of *L. major* isolates to medicine. However, the patients had different responses to SbV compounds. These findings are exactly comparable to our results.\[[@ref6]\]

In addition to all of the above-mentioned factors, noncompliance with treatment and incomplete treatment courses will expose the parasites to drug pressure and increase the chance of SbV resistance.\[[@ref32]\]

Conclusion {#sec1-5}
==========

Despite the proven intrinsic resistance of some *Leishmania* species (e.g. *L. infantum*, *L. tropica*, and *L. donovani*) to Glucantime, unresponsiveness of *L. major* to Glucantime is, in most cases, not due to its intrinsic resistance. Therefore, appropriate administration of the medicine under the supervision of skilled professionals, along with policies to ensure complete courses of treatment will lead to healing of the involved cases.
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